News Releases

25 Jun '21
Funds provide additional resources and runway for advancing the company's biosimilar pipeline. Reykjavik, Iceland June 24, 2021  – Alvotech Holdings SA today announced that it has entered into an amendment and restatement agreement with bondholders of its $300m convertible bond issued on December
25 Mar '21
Alvotech strongly disputes AbbVie’s allegations of wrongdoing relating to AVT02, Alvotech’s proposed biosimilar to HUMIRA® (adalimumab). Alvotech will vigorously defend against these allegations. Notably, AbbVie waited over three years from the purported date of the alleged wrongdoing to file its
15 Mar '21
Alvotech has successfully completed a second round of its US$ 100 million private placement, for US$ 35 million. The first round which was completed in October 2020, amounted to US$ 65 million. As part of the first round Shinhan from Korea, Baxter Healthcare SA from the US and ATHOS (Strüngmann
10 Dec '20
Fuji Pharma will exclusively commercialize the medicines in Japan – discussions between the parties continue over additional biosimilar candidates Alvotech and Japanese pharmaceutical company Fuji Pharma (Tokyo Stock Exchange: 4554) announce that they have agreed on an extension on their exclusive
Displaying 21 - 30 of 55